Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus)

Andrew G Hendrickx, F. ‐Ch Helm

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Teratologic evaluation of a mild tranquilizer being developed for human therapeutic use involved daily oral administration to 29 baboons P. cynocephalus during organogenesis according to three treatment regimens. In Phase I, 9 animals (3 groups of 3) received 2, 6, or 20 mg/kg CG 3033 per day for 28 consecutive days between 18 and 45 days gestation; in Phase II, 14 animals (7 groups of 2) were given 20 mg/kg CG 3033 for four consecutive days: 18–21, 22–25, 26–29, 30–33, 34–37, 38–41, or 42–45; and in Phase III, 6 animals (2 groups of 3) were administered 40 mg/kg daily between days 18–21 or 22–25 of gestation. No teratologic changes attributable to drug treatment were observed, and the abortion rate was within the range for controls.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalTeratology
Volume22
Issue number2
DOIs
StatePublished - 1980

Fingerprint

Papio cynocephalus
Thalidomide
Papio
Animals
Drug therapy
Pregnancy
Organogenesis
Induced Abortion
Therapeutic Uses
Oral Administration
Therapeutics
Pharmaceutical Preparations
supidimide

ASJC Scopus subject areas

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Cite this

Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus). / Hendrickx, Andrew G; Helm, F. ‐Ch.

In: Teratology, Vol. 22, No. 2, 1980, p. 179-182.

Research output: Contribution to journalArticle

Hendrickx, Andrew G ; Helm, F. ‐Ch. / Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus). In: Teratology. 1980 ; Vol. 22, No. 2. pp. 179-182.
@article{0e334dd626414d87ab1282997654acf9,
title = "Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus)",
abstract = "Teratologic evaluation of a mild tranquilizer being developed for human therapeutic use involved daily oral administration to 29 baboons P. cynocephalus during organogenesis according to three treatment regimens. In Phase I, 9 animals (3 groups of 3) received 2, 6, or 20 mg/kg CG 3033 per day for 28 consecutive days between 18 and 45 days gestation; in Phase II, 14 animals (7 groups of 2) were given 20 mg/kg CG 3033 for four consecutive days: 18–21, 22–25, 26–29, 30–33, 34–37, 38–41, or 42–45; and in Phase III, 6 animals (2 groups of 3) were administered 40 mg/kg daily between days 18–21 or 22–25 of gestation. No teratologic changes attributable to drug treatment were observed, and the abortion rate was within the range for controls.",
author = "Hendrickx, {Andrew G} and Helm, {F. ‐Ch}",
year = "1980",
doi = "10.1002/tera.1420220206",
language = "English (US)",
volume = "22",
pages = "179--182",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Nonteratogenicity of a structural analog of thalidomide in pregnant baboons (Papio cynocephalus)

AU - Hendrickx, Andrew G

AU - Helm, F. ‐Ch

PY - 1980

Y1 - 1980

N2 - Teratologic evaluation of a mild tranquilizer being developed for human therapeutic use involved daily oral administration to 29 baboons P. cynocephalus during organogenesis according to three treatment regimens. In Phase I, 9 animals (3 groups of 3) received 2, 6, or 20 mg/kg CG 3033 per day for 28 consecutive days between 18 and 45 days gestation; in Phase II, 14 animals (7 groups of 2) were given 20 mg/kg CG 3033 for four consecutive days: 18–21, 22–25, 26–29, 30–33, 34–37, 38–41, or 42–45; and in Phase III, 6 animals (2 groups of 3) were administered 40 mg/kg daily between days 18–21 or 22–25 of gestation. No teratologic changes attributable to drug treatment were observed, and the abortion rate was within the range for controls.

AB - Teratologic evaluation of a mild tranquilizer being developed for human therapeutic use involved daily oral administration to 29 baboons P. cynocephalus during organogenesis according to three treatment regimens. In Phase I, 9 animals (3 groups of 3) received 2, 6, or 20 mg/kg CG 3033 per day for 28 consecutive days between 18 and 45 days gestation; in Phase II, 14 animals (7 groups of 2) were given 20 mg/kg CG 3033 for four consecutive days: 18–21, 22–25, 26–29, 30–33, 34–37, 38–41, or 42–45; and in Phase III, 6 animals (2 groups of 3) were administered 40 mg/kg daily between days 18–21 or 22–25 of gestation. No teratologic changes attributable to drug treatment were observed, and the abortion rate was within the range for controls.

UR - http://www.scopus.com/inward/record.url?scp=0018965880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018965880&partnerID=8YFLogxK

U2 - 10.1002/tera.1420220206

DO - 10.1002/tera.1420220206

M3 - Article

C2 - 7444806

AN - SCOPUS:0018965880

VL - 22

SP - 179

EP - 182

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 2

ER -